227 related articles for article (PubMed ID: 21552019)
1. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
Clin Nucl Med; 2011 Jun; 36(6):434-9. PubMed ID: 21552019
[TBL] [Abstract][Full Text] [Related]
2. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer.
I HS; Kim SJ; Kim IJ; Kim K
Clin Nucl Med; 2012 May; 37(5):442-6. PubMed ID: 22475892
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
[TBL] [Abstract][Full Text] [Related]
7. Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
Kuo WH; Wu YC; Wu CY; Ho KC; Chiu PH; Wang CW; Chang CJ; Yu CT; Yen TC; Lin C
Acad Radiol; 2012 Jun; 19(6):685-92. PubMed ID: 22459646
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for mediastinal lymph node metastasis in non-small-cell lung cancer by PET/CT.
Xu ZQ; Xie LJ; Fan W; Duan XB; Cheng MH
Nucl Med Commun; 2014 May; 35(5):466-71. PubMed ID: 24535381
[TBL] [Abstract][Full Text] [Related]
9. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
Trister AD; Pryma DA; Xanthopoulos E; Kucharczuk J; Sterman D; Rengan R
Am J Clin Oncol; 2014 Apr; 37(2):135-9. PubMed ID: 23111361
[TBL] [Abstract][Full Text] [Related]
11. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
12. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
13. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.
Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Bogaert J; Maes A; Deneffe GJ; Nackaerts KL; Verschakelen JA; Lerut TE; Mortelmans LA; Demedts MG
J Clin Oncol; 1998 Jun; 16(6):2142-9. PubMed ID: 9626214
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
15. Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.
Li S; Zheng Q; Ma Y; Wang Y; Feng Y; Zhao B; Yang Y
PLoS One; 2013; 8(10):e78552. PubMed ID: 24205256
[TBL] [Abstract][Full Text] [Related]
16. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
17. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
Li M; Wu N; Liang Y; Zheng R; Liu Y; Zhang WJ; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):288-92. PubMed ID: 19615286
[TBL] [Abstract][Full Text] [Related]
18. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
19. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
20. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
